Walleye Trading
PTGX icon

Walleye Trading’s Protagonist Therapeutics PTGX Stock Holding History

Walleye Trading’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$453K Sell
4,300
-500
-10% -$44.3K ﹤0.01% 2648
2025
Q4 		$419K Buy
+4,800
New +$393K ﹤0.01% 2935
2023
Q3 		– Sell
-8,900
Closed -$246K – 5283
2023
Q2 		$246K Sell
8,900
-900
-9% -$22.5K ﹤0.01% 3300
2023
Q1 		$225K Buy
+9,800
New +$165K ﹤0.01% 3422

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return

Walleye Trading's PTGX Position: Q2 2023 in Review

Walleye Trading sold out of Protagonist Therapeutics (PTGX) in Q2 2023, closing a stake of 105,360 shares — an estimated $2.64M sold.

Walleye Trading first reported a position in PTGX in Q2 2018 and held it in 4 quarters. The position peaked at $2.42M in Q1 2023. 167 funds tracked by Wall St. Rank hold PTGX as of Q2 2023.

  • Walleye Trading reported no remaining Protagonist Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Walleye Trading sold 105,360 Protagonist Therapeutics shares in Q2 2023, an estimated $2.64M.
  • Walleye Trading first reported a position in Protagonist Therapeutics in Q2 2018 and held it in 4 quarters.
  • Walleye Trading's Protagonist Therapeutics position peaked at $2.42M in Q1 2023.
  • 167 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q2 2023.

Based on Walleye Trading's 13F filing for Q2 2023, filed 14 Aug 2023.